Biograil’s EUR 20 million financing underlines sustained investor appetite for enabling technologies that can de-risk biologics delivery and improve patient adherence. The Copenhagen-based company is positioning its BIONDD platform as a way to convert therapies that typically require injection into an oral capsule format, a value proposition that continues to attract both venture capital and strategic pharma interest.
Deal overview
Biograil announced a EUR 20 million funding round backed by Verve Ventures, Megatrend Invest and High-Tech Gründerfonds (HTGF). The wider syndicate spans Denmark, Switzerland, Germany, France and the United States, and includes Sanner Ventures, Evonik Venture Capital, Roquette Ventures and Eli Lilly, according to reported information.
The round builds on earlier financings, including a €3.2 million Seed 2 round that brought in Evonik Venture Capital, and a €8.5 million raise in 2025 aimed at supporting clinical testing after preclinical work.
Why this deal fits the current market
While biotech financing remains selective, platforms that sit at the intersection of formulation, delivery and manufacturability are drawing capital when they can show clear technical validation and credible development plans. Biograil’s story aligns with that pattern: it has reported extensive preclinical studies demonstrating oral delivery of injectable compounds with comparable bioavailability to subcutaneous injections.
Strategic validation is also a key signal in this segment. Eli Lilly previously signed a collaboration and license agreement with Biograil that included an upfront payment, research funding, development milestones, royalties and an equity investment. For investors, that kind of structure can indicate both technical diligence and a potential future commercial pathway, even if timelines and ultimate economics remain uncertain.
Use of proceeds and development path
Biograil has said later financing would be used to fund GLP nonclinical studies, prepare for GMP manufacturing and support planned Phase 1 clinical testing. For a drug-delivery platform, these steps are not administrative milestones. They are gating items that test whether the technology can move from preclinical promise into a reproducible, regulator-ready package, including scale-up and quality systems.
Key execution questions now shift from proof-of-concept to translation risk:
- Platform breadth vs lead-program focus: how many therapeutic modalities and molecules can BIONDD support without bespoke engineering each time?
- Manufacturing readiness: whether the formulation and encapsulation process can be scaled under GMP without eroding performance.
- Clinical endpoints and comparability: how Phase 1 design will demonstrate bioavailability, variability and safety versus injected comparators.
Syndicate composition: signals and implications
The investor mix is notable for two reasons.
First, it is international and repeat-backed. Megatrend Invest and Verve Ventures participated again after backing earlier rounds. HTGF, which led Biograil’s earlier seed syndicate, also joined later financings via its HTGF Opportunity growth fund. Repeat participation often signals that early technical and operational milestones have been met well enough to justify continued exposure.
Second, the syndicate blends venture capital, corporate venture and strategic pharma. With Evonik Venture Capital and Roquette Ventures in the group alongside Eli Lilly, Biograil will face heightened expectations around industrialisation pathways and partnerability, not just scientific novelty.
Copenhagen as a platform hub: evidence, not a conclusion
Biograil’s Copenhagen base and continued local support, alongside international participation, add to the picture of drug-delivery activity in the city. That said, available sources do not establish that Copenhagen’s broader biotech ecosystem has achieved sector-wide credibility. For now, this is better read as a company-specific validation than a definitive regional signal.
What to watch next
- Evidence that GLP studies and GMP preparation are progressing on schedule, with clear gating milestones
- Phase 1 trial design and whether endpoints convincingly show oral comparability to injected delivery
- Additional pharma collaborations that expand beyond a single strategic relationship
- Whether the company narrows to a lead asset to drive clinical proof, or continues broad platform positioning
- Signs of manufacturing and quality-system buildout sufficient for clinical and partner diligence